IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma announced its Phase 2 CALMA trial of IGC-AD1 is within six randomizations of enrollment closure, with topline data anticipated in Q4 2026. Q2 2026 financial results showed revenue of approximately $265,000 and a net loss of $3.0 million, or $0.03 per share. Cash and equivalents were approximately $331,000, supported by a $12 million credit facility with no outstanding debt.
Key figures
- Revenue
- 265000
- Drug Name
- IGC-AD1
- Phase Of Trial
- Phase 2
- Cash
- 331000
- Net loss
- 3000000
- Rd expenses
- 1400000
- Credit facility
- 12000000
- Debt conversion amount
- 1150000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.